CY1108710T1 - Παραγωγα της καρβαματης του 2η- η του 3η-βενζο[ε] ινδαζολ-1-υλιου, η παρασκευη τους και η θεραπευτικη εφαρμογη τους - Google Patents

Παραγωγα της καρβαματης του 2η- η του 3η-βενζο[ε] ινδαζολ-1-υλιου, η παρασκευη τους και η θεραπευτικη εφαρμογη τους

Info

Publication number
CY1108710T1
CY1108710T1 CY20091100042T CY091100042T CY1108710T1 CY 1108710 T1 CY1108710 T1 CY 1108710T1 CY 20091100042 T CY20091100042 T CY 20091100042T CY 091100042 T CY091100042 T CY 091100042T CY 1108710 T1 CY1108710 T1 CY 1108710T1
Authority
CY
Cyprus
Prior art keywords
alkyl
aryl
fluoroalkyl
alkoxy
preparation
Prior art date
Application number
CY20091100042T
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Christian Maloizel
Mireille Sevrin
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1108710T1 publication Critical patent/CY1108710T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Η εφεύρεση αφορά στις ενώσεις με το γενικό τύπο (I): όπου το W αντιπροσωπεύει ένα άτομο οξυγόνου ή θείου, τα Χ1, Χ2, Χ3 και Χ4 αντιπροσωπεύουν το καθένα, ανεξάρτητα το ένα από το άλλο, ένα άτομο υδρογόνου ή αλογόνου ή μία ομάδα κυανίου, C1-C6- αλκυλίου, C1-C6-φθοροαλκυλίου, C1-C6-αλκοξυλίου, C1-C6-φθορο- αλκοξυλίου, το Υ βρίσκεται στη θέση (Ν2) ή (Ν3), όταν το Υ βρίσκεται στη θέση (Ν2), το Υ αντιπροσωπεύει μία ομάδα C1-C6-αλκυλίου, C1-C6-φθοροαλκυλίου, αρυλίου ή ετεροαρυλίου, όταν το Υ βρίσκεται στη θέση (Ν3), το Υ αντιπροσωπεύει μία ομάδα αρυλίου ή ετεροαρυλίου, οι ομάδες αρυλίου ή ετεροαρυλίου είναι ενδεχομένως υποκατεστημένες με ένα ή περισσότερα άτομα ή με μία ή περισσότερες ομάδες που επιλέγονται από τα άτομα αλογόνου, τις ομάδες C1-C6-αλκυλίου, C1-C6- αλκοξυλίου, C1-C6-αλκυλο-θείου, C1-C6-αλκυλο-S(O)-, C1-C6-αλκυλο- S(O)2-, C1-C6-φθοροαλκυλίου, ο δεσμός στη θέση C4 ή C5 είναι διπλός ή απλός, τα R1 και R2 αντιπροσωπεύουν το καθένα, ανεξάρτητα το ένα από το άλλο, μία ομάδα αρυλίου, βενζυλίου ή C1-C6-αλκυλίου, ή ακόμη τα R1 και R2 σχηματίζουν, με το άτομο αζώτου που τα φέρει, έναν ετεροκυκλικό δακτύλιο ενδεχομένως υποκατεστημένο με μία ή περισσότερες ομάδες C1-C6-αλκυλίου ή βενζυλίου, σε κατάσταση βάσης ή ενός άλατος προσθήκης ενός οξέος, καθώς και στην κατάσταση ενός υδρίτη ή ενός επιδιαλυτωμένου χημικού σωματιδίου. Μέθοδος παρασκευής και θεραπευτική εφαρμογή.
CY20091100042T 2004-05-11 2009-01-14 Παραγωγα της καρβαματης του 2η- η του 3η-βενζο[ε] ινδαζολ-1-υλιου, η παρασκευη τους και η θεραπευτικη εφαρμογη τους CY1108710T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405055A FR2870239B1 (fr) 2004-05-11 2004-05-11 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
EP05770962A EP1747201B8 (fr) 2004-05-11 2005-05-10 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CY1108710T1 true CY1108710T1 (el) 2014-04-09

Family

ID=34947852

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100042T CY1108710T1 (el) 2004-05-11 2009-01-14 Παραγωγα της καρβαματης του 2η- η του 3η-βενζο[ε] ινδαζολ-1-υλιου, η παρασκευη τους και η θεραπευτικη εφαρμογη τους

Country Status (32)

Country Link
US (3) US7501449B2 (el)
EP (1) EP1747201B8 (el)
JP (1) JP4909889B2 (el)
KR (1) KR101165483B1 (el)
CN (1) CN100577648C (el)
AR (1) AR049090A1 (el)
AT (1) ATE411295T1 (el)
AU (1) AU2005251982B2 (el)
BR (1) BRPI0508563A (el)
CA (1) CA2557942C (el)
CR (1) CR8570A (el)
CY (1) CY1108710T1 (el)
DE (1) DE602005010418D1 (el)
DK (1) DK1747201T3 (el)
EC (1) ECSP066810A (el)
ES (1) ES2315898T3 (el)
FR (1) FR2870239B1 (el)
HR (1) HRP20090012T3 (el)
IL (1) IL177632A (el)
MA (1) MA28372A1 (el)
NO (1) NO20064073L (el)
NZ (1) NZ549330A (el)
PL (1) PL1747201T3 (el)
PT (1) PT1747201E (el)
RS (1) RS50724B (el)
RU (1) RU2379293C2 (el)
SI (1) SI1747201T1 (el)
TN (1) TNSN06258A1 (el)
TW (1) TWI349004B (el)
UA (1) UA85866C2 (el)
WO (1) WO2005121099A1 (el)
ZA (1) ZA200607244B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
WO2007088528A1 (en) * 2006-02-03 2007-08-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Microtubule targeting agents
CL2008000793A1 (es) * 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
AU2014292164C1 (en) * 2013-07-15 2018-09-27 Basf Se Pesticide compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
FR2741073B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
BR0113697A (pt) * 2000-09-06 2003-07-22 Neurogen Corp Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
DK1747201T3 (da) 2009-02-16
TW200604181A (en) 2006-02-01
AU2005251982B2 (en) 2011-04-28
US20120108584A1 (en) 2012-05-03
DE602005010418D1 (de) 2008-11-27
NO20064073L (no) 2006-11-06
US20090143380A1 (en) 2009-06-04
CA2557942C (fr) 2013-08-06
CA2557942A1 (fr) 2005-12-22
ATE411295T1 (de) 2008-10-15
UA85866C2 (uk) 2009-03-10
PL1747201T3 (pl) 2009-04-30
RU2379293C2 (ru) 2010-01-20
HK1104288A1 (en) 2008-01-11
HRP20090012T3 (en) 2009-02-28
US20070105932A1 (en) 2007-05-10
CR8570A (es) 2007-10-04
EP1747201B8 (fr) 2009-02-18
AR049090A1 (es) 2006-06-28
MA28372A1 (fr) 2006-12-01
CN100577648C (zh) 2010-01-06
KR101165483B1 (ko) 2012-07-13
AU2005251982A1 (en) 2005-12-22
SI1747201T1 (sl) 2009-04-30
FR2870239A1 (fr) 2005-11-18
ECSP066810A (es) 2006-11-16
US8114899B2 (en) 2012-02-14
TNSN06258A1 (fr) 2007-12-03
KR20070007796A (ko) 2007-01-16
US7501449B2 (en) 2009-03-10
EP1747201A1 (fr) 2007-01-31
RS50724B (sr) 2010-08-31
US8258168B2 (en) 2012-09-04
IL177632A (en) 2012-07-31
EP1747201B1 (fr) 2008-10-15
CN1930131A (zh) 2007-03-14
RU2006132325A (ru) 2008-03-20
ES2315898T3 (es) 2009-04-01
PT1747201E (pt) 2009-01-19
WO2005121099A1 (fr) 2005-12-22
JP2007537212A (ja) 2007-12-20
NZ549330A (en) 2010-08-27
TWI349004B (en) 2011-09-21
IL177632A0 (en) 2006-12-31
JP4909889B2 (ja) 2012-04-04
ZA200607244B (en) 2008-04-30
BRPI0508563A (pt) 2007-08-14
FR2870239B1 (fr) 2006-06-16

Similar Documents

Publication Publication Date Title
CY1111706T1 (el) Παραγωγα αρυλο- και ετεροαρυλο-πιπεριδινοκαρβοξυλικων αλατων, η παρασκευη τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
CY1110317T1 (el) Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης
CY1113836T1 (el) Ειδικη γλυκοκορτικοστεροειδης ενωση η οποια εχει αντιφλεγμονωδη δραση
CY1113002T1 (el) Παραγωγα μακροκυκλικης κιναζολινης ως αντιπολλαπλασιαστικοι παραγοντες
CY1113505T1 (el) Νεο παραγωγο ανθρανιλικου οξεος ή αλας αυτου
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
CY1117142T1 (el) Παραγωγο αμινοπυραζολης
CY1109345T1 (el) ΠΑΡΑΓΩΓΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8-ΥΠΕΡΦΘΟΡΟΑΛΚΥΛΟ-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ (1,2-a) ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
CY1109231T1 (el) Παραγωγα πεπεριδιναλκυλο καρβονικων αλατων, η προετοιμασια τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
CY1105797T1 (el) Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα
CY1109544T1 (el) Παραγωγα της οξαζολιδινονης και η χρηση τους σαν αντιβιοτικα
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
CY1107117T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα σαν αναστολεις της p38
CY1111428T1 (el) Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης
CY1113813T1 (el) Νεες ενωσεις που εχουν ανασταλτικη δραστικοτητα εναντια στον εξαρτωμενο απο το νατριο μεταφορεα
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
CY1112754T1 (el) Μεθοδοι και ενδιαμεσα για την παρασκευη παραγωγων ν4-φαινυλ-κιναζολιν-4-αμινης
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
PH12013501178A1 (en) Fused heterocyclic compound and use for pest control thereof
ECSP077180A (es) Compuestos, composiciones y métodos
EP1487428A4 (en) (E) - 2,6-DIALCOXYSTYRYL SUBSTITUTED AMINO-BENZYLSULFONES SUBSTITUTED IN POSITION 4 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
ATE543807T1 (de) Verstärker von glutamat-rezeptoren